Eli Lilly Analyst Price Targets - Benzinga

Eli Lilly and Co

LLYNYSE

Trade with Public

Trade with Public

$1149.85

-7.23-0.62%

Últ. Act.: Oct 1, 4:53 PM

$1150.99

-6.09-0.53%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Dividendos Comparar Informe de acciones

Eli Lilly Analyst Price Targets

Wall Street analyst price targets and consensus rating for Eli Lilly (LLY).

Price Target Range — 9 Quarters

Analyst Consensus — 21 Analysts

20Buy

1Hold

Consensus RatingBuy# Analysts21Avg. Consensus PT$1245Upside to Avg. PT+8.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 28, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$1400→$1500
Sep 22, 2026	TD Cowen	Steve Scala	Maintained	Buy	$1250
Sep 18, 2026	Guggenheim	Seamus Fernandez	PT Raise	Buy	$1273→$1284
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Reduce	$850→$940
Aug 7, 2026	Truist Securities	Robyn Karnauskas	PT Raise	Buy	$1370→$1376
Aug 6, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$1280→$1330
Aug 6, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$1350→$1410
Jul 15, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$1500→$1600
Jul 14, 2026	Bernstein	Courtney Breen	PT Raise	Outperform	$1300→$1385
Jul 13, 2026	UBS	Michael Yee	PT Raise	Buy	$1250→$1425
Jul 13, 2026	Guggenheim	Seamus Fernandez	PT Cut	Buy	$1235→$1273
Jul 10, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$1251→$1334
Jul 8, 2026	Truist Securities	Robyn Karnauskas	PT Raise	Buy	$1281→$1370
Jul 8, 2026	Morgan Stanley	Terence Flynn	PT Raise	Overweight	$1344→$1347
Jul 8, 2026	RBC Capital	Trung Huynh	PT Raise	Outperform	$1250→$1500
Jul 7, 2026	JP Morgan	Chris Schott	PT Raise	Overweight	$1300→$1400
Jul 6, 2026	Cantor Fitzgerald	Carter Gould	PT Raise	Overweight	$1230→$1350
Jun 25, 2026	Leerink Partners	David Risinger	PT Raise	Outperform	$1119→$1232
Jun 9, 2026	Jefferies	Akash Tewari	PT Raise	Buy	$1330→$1350
May 26, 2026	B of A Securities	Jason Gerberry	PT Raise	Buy	$1133→$1251

More with Benzinga EdgeGet Access

Analyst Ratings News

Eli Lilly Could Be a ‘$2,000 Stock’ in the Next 3 to 4 Years, Says Home Depot Co-Founder Ken Langone

Home Depot co-founder Ken Langone says Eli Lilly could hit $2,000 in 3 to 4 years, challenging Home Depot as his top portfolio holding.

Rishabh Mishra

Eli Lilly Gets Full FDA Approval for Inluriyo in ESR1-Mutated Breast Cancer

The FDA fully approves Eli Lilly's Inluriyo and Verzenio combination for advanced breast cancer, doubling progression-free survival.

Vandana Singh

PRO
TD Cowen Reiterates Buy on Eli Lilly, Maintains $1250 Price Target

TD Cowen analyst Steve Scala reiterates Eli Lilly (NYSE:LLY) with a Buy and maintains $1250 price target.

Benzinga Newsdesk

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

U.S. stocks ended mixed; the Dow had its worst week since March. Benzinga highlights top picks from five accurate analysts, including ON, AXSM and LLY.

Avi Kapoor

This $3 Biotech Could Be Worth $11.45, Analyst Says

William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.

Vandana Singh

Eli Lilly Diabetes Drug Franchise Remains Strong, Analyst Praises Foundayo Trajectory

Guggenheim raises PT to $1,284, citing strong tirzepatide and improving Foundayo trends; estimates exceed consensus.

Priya Nigam